Marcelo F. Di Carli, Md, Facc

This study looked at whether tildrakizumab, a drug already approved for psoriasis, can improve blood flow to the heart in people with moderate-to-severe psoriasis. 36 adults took the drug for 6 months, and researchers measured heart function using special scans. The goal was to s…